Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Subclinical Antibody-mediated Rejection in Kidney Transplant
NCT02113891Phase 2Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2015
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Feb 2015; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02113891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113891.